Home
Newsletter
Events
Blogs
Reports
Graphics
RSS
About Us
Contact Us
Write for Us
Media Info
Advertising Info
Eli Lilly

Former FDA Official Testifies that Eli Lilly Lied about Drug Side Effects

Saturday, September 06, 2008 by: David Gutierrez, staff writer
Tags: Eli Lilly, health news, Natural News


Most Viewed Articles
https://www.naturalnews.com/024089_Eli_Lilly_drug_FDA.html
Delicious
diaspora
Print
Email
Share

(NaturalNews) Pharmaceutical company Eli Lilly concealed the risks of its schizophrenia drug Zyprexa from U.S. regulators in order to increase its profits, a former FDA official has testified in Alaska court.

The state of Alaska is suing Eli Lilly to recover the money that the state Medicaid system paid out to treat the serious health problems caused by Zyprexa. John Gueriguian, who was an FDA employee for 20 years, was hired by the prosecution to analyze internal Eli Lilly documents.

Gueriguian testified that Eli Lilly knew as early as 1998 that Zyprexa increased the risk of developing diabetes, but did not issue warnings about those effects until 2007.

"Simply put, it's putting profit over the concern of the consumer," Gueriguian said.

Zyprexa is Eli Lilly's top-selling drug, generating $4.8 billion in 2007 alone. It is sold in more than 80 countries worldwide.

When the drug was approved by the FDA in 1996, doctors quickly began to report that patients were experiencing severe weight gain, high blood sugar and diabetes. By 1998, the evidence from these reports and from clinical trials was overwhelming enough that Eli Lilly should have warned doctors about the side effects, Gueriguian said.

Internal emails show that company employees were aware of the risks, and that consultants had raised concerns about them.

"I do believe [the consultants] made a very strong point that unless we come clean on this, it could get much more serious than we might anticipate," an email from October 2000 read.

In 2002, Japanese regulators imposed requirements that Eli Lilly warn doctors about Zyprexa's diabetes risks. Even after this occurred, however, the company's U.S. policy was still to pretend the issue did not exist.

"We will NOT proactively address the diabetes concerns," an internal company memo reads, instructing sales representatives to talk about diabetes only if doctors bring it up first.

In 2007, Eli Lilly updated Zyprexa's label to warn of severe increases to weight and blood sugar.

Receive Our Free Email Newsletter

Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.


comments powered by Disqus


Natural News Wire (Sponsored Content)

Science.News
Science News & Studies
Medicine.News
Medicine News and Information
Food.News
Food News & Studies
Health.News
Health News & Studies
Herbs.News
Herbs News & Information
Pollution.News
Pollution News & Studies
Cancer.News
Cancer News & Studies
Climate.News
Climate News & Studies
Survival.News
Survival News & Information
Gear.News
Gear News & Information
Glitch.News
News covering technology, stocks, hackers, and more